


## Factsheet: Governance of the IMI Joint Undertaking

### Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) has been set up by the Council Regulation EC N° 73/2008 which came into force on 7 February 2008. This Joint Undertaking implements the first of its kind public-private partnership between the pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the European Commission. The JU's structure consists of three distinct bodies: the IMI JU Governing Board, the IMI JU Executive Director with the Executive Office and the IMI Scientific Committee. The IMI JU is supported by two external advisory bodies: the IMI Member States Representatives Group and the Stakeholder Forum.



### The Governing Board

The Governing Board is the main decision-making body of the IMI JU. It carries the overall responsibility for the operations of the undertaking and oversees the implementation of its activities. It therefore guarantees the fulfilment of the objectives set by the IMI JU, namely overcoming bottlenecks in European pharmaceutical R&D and supporting biomedical research for the benefit of patients.

A first board meeting took place on 3 March 2008 which focused in particular on the 2008 key priorities for the IMI JU: launching the first call for proposals and continuing towards making the IMI JU autonomous. The Governing Board approved the draft scientific priorities for the first IMI call, which will be presented in detail at the launch event of the first IMI Call for Proposals, taking place in Brussels on 30 April 2008.

### Who are the Members of the IMI Governing Board?

The Governing Board is composed of ten board members representing equally the two Founding Members of the IMI JU: five from the European Commission, representing the European Community, and five from the European Federation of Pharmaceutical Industries and Associations (EFPIA), representing the research based pharmaceutical industry in Europe.

- Jonathan Knowles, Head of Group Research – ROCHE, **Chair**
- Daniel Jacob, Deputy Director-General - Political Framework, DG RTD, **Deputy Chair**
- Brian Ager, Director General – EFPIA
- Franco Biscontin, Director – Resources, DG RTD
- Andreas Busch, Executive Vice President - Head of Global Drug Discovery - Bayer Health-Care
- Jackie Hunter, Senior V-P & Head, Neurology Centre of Excellence for Drug Discovery – GSK
- Carlo Incerti, Head of R&D Europe – GENZYME
- Georgette Lalis, Director – Consumer Goods, DG ENTR
- Andrzej Jan Rys, Director – Public Health and Risk assessment, DG SANCO
- Zoran Stančič, Deputy Director-General – Scientific advances, DG RTD

### **The Executive Director**

The Executive Director is the chief executive responsible for the day-to-day management of the IMI JU in accordance with the decisions of the Governing Board. Alain Vanvossel has been appointed as Interim Executive Director, and will be responsible until the official Executive Director takes up his/her function. The Executive Director is supported by the staff of the Executive Office.

### **The Scientific Committee**

The Scientific Committee is an advisory body to the Governing Board and will be supported by the Executive Office. The Scientific Committee is currently being set up by inviting Member States and Associated Countries to submit proposals for candidates. The Scientific Committee will consist of no more than 15 members.

These members will have scientific competencies and expertise covering the complete drug development process needed to make strategic science-based recommendations for the IMI JU. They will furthermore advise on the continued relevance of the Research Agenda (which includes the scientific priorities) and recommend any necessary amendments.